Table 5 List of recorded MSCs treatment-based clinical studies for COVID-19 (https://clinicaltrials.gov/)
MSCs types | Study design | Population | Results or aims | NCT Number |
|---|---|---|---|---|
WJ-MSCs | Phase I Interventional | 5 (18Â years and older) | The first result shows that recovery of clinical signs | NCT04313322 |
Autologous AD-MSCs (Celltex-Ad-MSCs) | Phase II multicenter, double-blind, randomized, placebo-control | 200 (18Â years and older) | The first result shows that this method have no side effects and tolerability | NCT04444271 |
MSCs | Prospective, Randomized Phase II | 20 Age: 18–65 | Occurrence of SARS-CoV-2 in trial and control group first result: total survivorship at 30 days after-treatment | NCT04336254 |
Allogeneic Human Dental Pulp Mesenchymal | Single-center, prospective, randomized | 20 Age: 18 − 65 | The first result shows that time for clinical recovery | NCT04429763 |
UC-MSCs | Phase II | 30 Age: 18 − 79 | The first result shows that clinical decline or dying | NCT04416139 |
Allogeneic UC-MSCs | Pilot experiment | 10 (18Â years and older) | The first result: clinical, biochemical, inflammatory, and immune alters | NCT04315987 |
Allogeneic HB-AD-MSCs | Phase 2 (clinical trials performed early in Phase I) | 90 (18Â years and older) | Early Consequence: alteration in the clinical situation | NCT04348435 |
MSCs derived from WJ of UC | Early Phase I | 9 18Â years and older | Early Consequence: Oxygen Saturation | NCT04456361 |
HB-AD-MSCs | Phase II, open label study, single-center trial | 56 Child, Adult, Older Adult | Early Consequence: occurrence of hospitalization and signs related on SARS-CoV-2 | NCT04349631 |
MSCs | Phase II, Interventional | 20 18Â years to 70Â years | Early Consequence: evaluation of pneumonia recovery and adverse events | NCT04252118 |
UC-MSCs | Phase II, Multicenter, randomized-controlled trial, double-blind experiment | 100 18Â years to 75Â years | Assessment of pneumonia Recovery | NCT04288102 |
UB-MSCs | Phase II RCT | 20 30Â years to 70Â years | Evaluation of pneumonia and adverse effects | NCT04437823 |
Allogenic pooled olfactory mucosa-derived MSC | Phase I, Phase II | 40 Age: 18 − 70 | Number of infected persons treated | NCT04382547 |
UC-MSCs + Heparin along with best supportive treatment | Phase I/II double-blinded experiment | 24 (18 years and older) | Harmlessness will be determined via the occurrence of intense side effects as measured via curing physician | NCT04355728 |
hUC-MSC (BX-U001) + supportive treatment | Phase1 | 9 18–80 years old | Assessment of safety | NCT03828344 |
MSCs in Inflammation-Resolution Programs of COVID-19 with ARDS | Prospective phase II trial | 40 18Â years and older | Recovery of lung damage score | NCT04377334 |
XCEL-UMC-BETA (WJ- MSC) | Phase 1, Phase 2, prospective, double-blind, randomized-controlled trial, parallel, placebo-controlled pilot | 30 Age: 18 − 75 | Number of infected persons who expired | NCT04390139 |
ACT-20-MSC | Phase 1, Phase II randomized-controlled trial, placebo-controlled trial | 70 Age: 18–85 | Death on day 30 | NCT04398303 |
MultiStem | Phase II and III trial | 400 Age: 18–89 | Ventilator-Removal Days. Lack of side effects and tolerability | NCT04367077 |
MSCs-derived exosomes | Phase 1 | 24 18 Years to 75Â years | Time to clinical recovery and safety | NCT04445220 |
UC-MSCs | Phase 2 | 16 Age: 18–80 | Ventilation OI | NCT04269525 |
BM-MSCs | Phase I/II randomized-controlled trial | 20 18Â years to 75Â years | Assessment of pneumonia recovery and harmlessness evaluation | NCT04346368 |
BM-Allo.MSC | Phase 1b randomized, double-blind, placebo-controlled study | 45 Age: 18–80 | Occurrence of AEs, death and its reason, and number of ventilator-removal days | NCT04397796 |